Dipeptidyl-peptidase 3 and IL-6: potential biomarkers for diagnostics in COVID-19 and association with pulmonary infiltrates.
Artificial intelligence
COVID-19
Dipeptidyl-peptidase 3
IL-6
Pulmonary infiltrates
SARS-CoV-2
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
21 Sep 2023
21 Sep 2023
Historique:
received:
05
04
2023
accepted:
08
09
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
aheadofprint
Résumé
Coronavirus SARS-CoV-2 spread worldwide, causing a respiratory disease known as COVID-19. The aim of the present study was to examine whether Dipeptidyl-peptidase 3 (DPP3) and the inflammatory biomarkers IL-6, CRP, and leucocytes are associated with COVID-19 and able to predict the severity of pulmonary infiltrates in COVID-19 patients versus non-COVID-19 patients. 114 COVID-19 patients and 35 patients with respiratory infections other than SARS-CoV-2 were included in our prospective observational study. Blood samples were collected at presentation to the emergency department. 102 COVID-19 patients and 28 non-COVID-19 patients received CT imaging (19 outpatients did not receive CT imaging). If CT imaging was available, artificial intelligence software (CT Pneumonia Analysis) was used to quantify pulmonary infiltrates. According to the median of infiltrate (14.45%), patients who obtained quantitative CT analysis were divided into two groups (> median: 55 COVID-19 and nine non-COVID-19, ≤ median: 47 COVID-19 and 19 non-COVID-19). DPP3 was significantly elevated in COVID-19 patients (median 20.85 ng/ml, 95% CI 18.34-24.40 ng/ml), as opposed to those without SARS-CoV-2 (median 13.80 ng/ml, 95% CI 11.30-17.65 ng/ml; p < 0.001, AUC = 0.72), opposite to IL-6, CRP (each p = n.s.) and leucocytes (p < 0.05, but lower levels in COVID-19 patients). Regarding binary logistic regression analysis, higher DPP3 concentrations (OR = 1.12, p < 0.001) and lower leucocytes counts (OR = 0.76, p < 0.001) were identified as significant and independent predictors of SARS-CoV-2 infection, as opposed to IL-6 and CRP (each p = n.s.). IL-6 was significantly increased in patients with infiltrate above the median compared to infiltrate below the median both in COVID-19 (p < 0.001, AUC = 0.78) and in non-COVID-19 (p < 0.05, AUC = 0.81). CRP, DPP3, and leucocytes were increased in COVID-19 patients with infiltrate above median (each p < 0.05, AUC: CRP 0.82, DPP3 0.70, leucocytes 0.67) compared to infiltrate below median, opposite to non-COVID-19 (each p = n.s.). Regarding multiple linear regression analysis in COVID-19, CRP, IL-6, and leucocytes (each p < 0.05) were associated with the degree of pulmonary infiltrates, as opposed to DPP3 (p = n.s.). DPP3 showed the potential to be a COVID-19-specific biomarker. IL-6 might serve as a prognostic marker to assess the extent of pulmonary infiltrates in respiratory patients.
Identifiants
pubmed: 37733154
doi: 10.1007/s10238-023-01193-z
pii: 10.1007/s10238-023-01193-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
(2023) China: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/region/wpro/country/cn . Accessed 20 Jan 2023
Lee CM, Snyder SH. Dipeptidyl-aminopeptidase III of rat brain. Selective affinity for enkephalin and angiotensin. J Biol Chem. 1982;257:12043–50.
doi: 10.1016/S0021-9258(18)33674-3
pubmed: 6749851
Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J. 2011;278:3256–76. https://doi.org/10.1111/j.1742-4658.2011.08275.x .
doi: 10.1111/j.1742-4658.2011.08275.x
pubmed: 21794094
Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med. 2019;3:943–53. https://doi.org/10.1373/jalm.2018.027995 .
doi: 10.1373/jalm.2018.027995
pubmed: 31639686
Blet A, Deniau B, Santos K, et al. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care. 2021;25:61. https://doi.org/10.1186/s13054-021-03471-2 .
doi: 10.1186/s13054-021-03471-2
pubmed: 33588925
pmcid: 7885215
Dépret F, Amzallag J, Pollina A, et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. Crit Care. 2020;24:168. https://doi.org/10.1186/s13054-020-02888-5 .
doi: 10.1186/s13054-020-02888-5
pubmed: 32321571
pmcid: 7178561
Frigyesi A, Lengquist M, Spångfors M, et al. Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality. J Intensive Care. 2021;9:52. https://doi.org/10.1186/s40560-021-00561-9 .
doi: 10.1186/s40560-021-00561-9
pubmed: 34429159
pmcid: 8386069
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238–43. https://doi.org/10.1074/jbc.M002615200 .
doi: 10.1074/jbc.M002615200
pubmed: 10924499
Moon J-Y. Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension. Electrolyte Blood Press. 2013;11:41–5. https://doi.org/10.5049/EBP.2013.11.2.41 .
doi: 10.5049/EBP.2013.11.2.41
pubmed: 24627703
pmcid: 3950224
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4. https://doi.org/10.1038/nature02145 .
doi: 10.1038/nature02145
pubmed: 14647384
pmcid: 7095016
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052 .
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
van Lier D, Deniau B, Santos K, et al. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study. ERJ Open Res. 2023. https://doi.org/10.1183/23120541.00342-2022 .
doi: 10.1183/23120541.00342-2022
pubmed: 36628268
pmcid: 9571166
Heinicke U, Adam E, Sonntagbauer M, von Knethen A, Zacharowski K, Neb H. Angiotensin II treatment in COVID-19 patients: More risk than benefit? A single-center experience. Crit Care. 2020;24:409. https://doi.org/10.1186/s13054-020-03143-7 .
doi: 10.1186/s13054-020-03143-7
pubmed: 32646469
pmcid: 7347263
Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991;91:23–9. https://doi.org/10.1016/0002-9343(91)90069-a .
doi: 10.1016/0002-9343(91)90069-a
pubmed: 1907101
Bacci MR, Leme RCP, Zing NPC, et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz J Med Biol Res. 2015;48:427–32. https://doi.org/10.1590/1414-431X20144402 .
doi: 10.1590/1414-431X20144402
pubmed: 25714883
pmcid: 4445666
Glynn P, Coakley R, Kilgallen I, Murphy N, O’Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax. 1999;54:51–5. https://doi.org/10.1136/thx.54.1.51 .
doi: 10.1136/thx.54.1.51
pubmed: 10343632
pmcid: 1745351
Martínez R, Menéndez R, Reyes S, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011;37:393–9. https://doi.org/10.1183/09031936.00040710 .
doi: 10.1183/09031936.00040710
pubmed: 20595152
Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123–30. https://doi.org/10.1080/22221751.2020.1770129 .
doi: 10.1080/22221751.2020.1770129
pubmed: 32475230
pmcid: 7473317
Potere N, Batticciotto A, Vecchié A, et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021;17:601–18. https://doi.org/10.1080/1744666X.2021.1919086 .
doi: 10.1080/1744666X.2021.1919086
pubmed: 33874829
Chen L-D, Zhang Z-Y, Wei X-J, et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 2020;21:201. https://doi.org/10.1186/s12931-020-01465-2 .
doi: 10.1186/s12931-020-01465-2
pubmed: 32727465
pmcid: 7389162
Homayounieh F, Bezerra Cavalcanti Rockenbach MA, Ebrahimian S, et al. Multicenter assessment of CT pneumonia analysis prototype for predicting disease severity and patient outcome. J Digit Imaging. 2021;34:320–9. https://doi.org/10.1007/s10278-021-00430-9 .
doi: 10.1007/s10278-021-00430-9
pubmed: 33634416
pmcid: 7906242
Gouda W, Yasin R. COVID-19 disease: CT pneumonia analysis prototype by using artificial intelligence, predicting the disease severity. Egypt J Radiol Nucl Med. 2020;51:1–11. https://doi.org/10.1186/s43055-020-00309-9 .
doi: 10.1186/s43055-020-00309-9
Huang L, Han R, Ai T, et al. Serial quantitative chest CT assessment of COVID-19: a deep learning approach. Radiol Cardiothorac Imaging. 2020;2:e200075. https://doi.org/10.1148/ryct.2020200075 .
doi: 10.1148/ryct.2020200075
pubmed: 33778562
pmcid: 7233442
Ardali Duzgun S, Durhan G, Basaran Demirkazik F, et al. AI-based quantitative CT analysis of temporal changes according to disease severity in COVID-19 pneumonia. J Comput Assist Tomogr. 2021;45:970–8. https://doi.org/10.1097/RCT.0000000000001224 .
doi: 10.1097/RCT.0000000000001224
pubmed: 34581706
pmcid: 8607923
Okuma T, Hamamoto S, Maebayashi T, et al. Quantitative evaluation of COVID-19 pneumonia severity by CT pneumonia analysis algorithm using deep learning technology and blood test results. Jpn J Radiol. 2021;39:956–65. https://doi.org/10.1007/s11604-021-01134-4 .
doi: 10.1007/s11604-021-01134-4
pubmed: 33988788
pmcid: 8120249
Karami H, Derakhshani A, Ghasemigol M, et al. Weighted gene co-expression network analysis combined with machine learning validation to identify key modules and hub genes associated with SARS-CoV-2 infection. J Clin Med. 2021. https://doi.org/10.3390/jcm10163567 .
doi: 10.3390/jcm10163567
pubmed: 34441862
pmcid: 8397209
Schlossbauer MH, Hubauer U, Stadler S, et al. The role of the tubular biomarkers NAG, kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with chest pain before contrast media exposition. Biomark Med. 2019;13:379–92. https://doi.org/10.2217/bmm-2018-0275 .
doi: 10.2217/bmm-2018-0275
pubmed: 30920848
Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021;191:4–17. https://doi.org/10.1016/j.ajpath.2020.08.009 .
doi: 10.1016/j.ajpath.2020.08.009
pubmed: 32919977
pmcid: 7484812
Magliocca A, Omland T, Latini R. Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more. Eur J Heart Fail. 2020;22:300–2. https://doi.org/10.1002/ejhf.1649 .
doi: 10.1002/ejhf.1649
pubmed: 31840335
Takagi K, Blet A, Levy B, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail. 2020;22:279–86. https://doi.org/10.1002/ejhf.1600 .
doi: 10.1002/ejhf.1600
pubmed: 31472039
Deniau B, Blet A, Santos K, et al. Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study. PLoS ONE. 2020;15:e0238039. https://doi.org/10.1371/journal.pone.0238039 .
doi: 10.1371/journal.pone.0238039
pubmed: 32853284
pmcid: 7451654
Deniau B, Rehfeld L, Santos K, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail. 2020;22:290–9. https://doi.org/10.1002/ejhf.1601 .
doi: 10.1002/ejhf.1601
pubmed: 31472040
Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open. 2020;4:e138–44. https://doi.org/10.1055/s-0040-1713678 .
doi: 10.1055/s-0040-1713678
pubmed: 32607467
pmcid: 7319800
Ekholm M, Kahan T, Jörneskog G, Bröijersen A, Wallén NH. Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. Thromb Res. 2009;124:110–5. https://doi.org/10.1016/j.thromres.2008.12.040 .
doi: 10.1016/j.thromres.2008.12.040
pubmed: 19195683
Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10. https://doi.org/10.1182/blood.V74.1.1.1 .
doi: 10.1182/blood.V74.1.1.1
pubmed: 2473791
Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992;258:593–7. https://doi.org/10.1126/science.1411569 .
doi: 10.1126/science.1411569
pubmed: 1411569
Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. https://doi.org/10.1016/s0065-2776(08)60532-5 .
doi: 10.1016/s0065-2776(08)60532-5
pubmed: 8379461
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84:7251–5. https://doi.org/10.1073/pnas.84.20.7251 .
doi: 10.1073/pnas.84.20.7251
pubmed: 2444978
pmcid: 299269
Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243–54.
doi: 10.1182/blood.V86.4.1243.bloodjournal8641243
pubmed: 7632928
Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005;175:3463–8. https://doi.org/10.4049/jimmunol.175.6.3463 .
doi: 10.4049/jimmunol.175.6.3463
pubmed: 16148087
Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992;215:356–62. https://doi.org/10.1097/00000658-199204000-00009 .
doi: 10.1097/00000658-199204000-00009
pubmed: 1558416
pmcid: 1242452
Andrijevic I, Matijasevic J, Andrijevic L, Kovacevic T, Zaric B. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann Thorac Med. 2014;9:162–7. https://doi.org/10.4103/1817-1737.134072 .
doi: 10.4103/1817-1737.134072
pubmed: 24987476
pmcid: 4073574
Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med. 2012;12:6. https://doi.org/10.1186/1471-2466-12-6 .
doi: 10.1186/1471-2466-12-6
pubmed: 22348735
pmcid: 3311562
Ramírez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39:2211–7. https://doi.org/10.1097/CCM.0b013e3182257445 .
doi: 10.1097/CCM.0b013e3182257445
pubmed: 21705887
Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–73. https://doi.org/10.1378/chest.107.4.1062 .
doi: 10.1378/chest.107.4.1062
pubmed: 7705118
Bauer TT, Montón C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000;55:46–52. https://doi.org/10.1136/thorax.55.1.46 .
doi: 10.1136/thorax.55.1.46
pubmed: 10607801
pmcid: 1745592
Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761–9. https://doi.org/10.1002/art.20303 .
doi: 10.1002/art.20303
pubmed: 15188351
Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. https://doi.org/10.1016/S0140-6736(08)60454-7 .
doi: 10.1016/S0140-6736(08)60454-7
pubmed: 18358927
Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C. A new approach to the management of COVID-19. Antagonists of IL-6: siltuximab. Adv Ther. 2022;39:1126–48. https://doi.org/10.1007/s12325-022-02042-3 .
doi: 10.1007/s12325-022-02042-3
pubmed: 35072887
pmcid: 8784859
Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci. 2021;18:1356–62. https://doi.org/10.7150/ijms.53564 .
doi: 10.7150/ijms.53564
pubmed: 33628091
pmcid: 7893562
Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30:4381–9. https://doi.org/10.1007/s00330-020-06801-0 .
doi: 10.1007/s00330-020-06801-0
pubmed: 32193638
pmcid: 7088323
Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30:3306–9. https://doi.org/10.1007/s00330-020-06731-x .
doi: 10.1007/s00330-020-06731-x
pubmed: 32055945
pmcid: 7087663
Song F, Shi N, Shan F, et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295:210–7. https://doi.org/10.1148/radiol.2020200274 .
doi: 10.1148/radiol.2020200274
pubmed: 32027573
Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020;295:200463. https://doi.org/10.1148/radiol.2020200463 .
doi: 10.1148/radiol.2020200463
pubmed: 32077789
Wu J, Wu X, Zeng W, et al. Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features. Invest Radiol. 2020;55:257–61. https://doi.org/10.1097/RLI.0000000000000670 .
doi: 10.1097/RLI.0000000000000670
pubmed: 32091414
pmcid: 7147284
Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425–34. https://doi.org/10.1016/S1473-3099(20)30086-4 .
doi: 10.1016/S1473-3099(20)30086-4
pubmed: 32105637
pmcid: 7159053
Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investig Radiol. 2020;55:327–31. https://doi.org/10.1097/RLI.0000000000000672 .
doi: 10.1097/RLI.0000000000000672